Like any successful business, we continue to evolve, progress, and achieve new goals. We would like to share these changes with you, so that you are always informed about the latest news.
Munich, 24th November 2020 – The Munich-based medical technology company was selected from 189 nominations by an independent jury and won the 1st main prize
The Bavarian Innovation Award is a joint initiative of the Bavarian Ministry of Economic Affairs, the Association of Bavarian Chambers of Industry and Commerce and the Association of Bavarian Chambers of Trade. Since 2012 it has been awarded every two years to Bavarian companies in recognition of outstanding innovative products, processes and technology-oriented services.
Bavaria’s Secretary of Economic Affairs, Roland Weigert, awarded the prize to ADVITOS at the virtual event on November 23, 2020. “In intensive care units, 60 % of patients die of multiple organ failure. There is a technology from Upper Bavaria that will save lives here. For the first time in the world, it has been possible to combine multiorgan support of the liver, lungs and kidneys and the direct correction of the blood pH in a single device. This is so outstanding that the ADVITOS is being honored”.
ADVITOS is based in the Munich Technology Centre (MTZ), which focuses on supporting and maintaining technology and innovation-oriented companies and promoting start-ups in the region. From there the 55 employees develop, produce and market the innovative ADVOS procedure for the treatment of multiorgan failure.
Assoc. Prof. Dr. med. Bernhard Kreymann, founder of ADVITOS and himself a nephrologist, emphasises that it is not enough to simply have an idea. “You can have an idea, but its implementation is all the more important. That is why this prize is a huge acknowledgement for the entire team, who put a lot of hard work into our product”. Kreymann further emphasizes that especially in times of COVID-19 it is important to relieve the nursing and medical staff in the hospitals. The ADVOS procedure can make this possible and is already being used to treat COVID-19 patients.
Munich, 28th September 2020 – Patients with severe multiple organ failure due to COVID-19 have been treated with the ADVOS (ADVanced Organ Support) device at the Munich University Hospital rechts der Isar and a first case has been reported in detail. The team around Prof. Dr. med. Wolfgang Huber consider a multiple organ support with low invasiveness a promising approach for severely ill patients with organ dysfunction.
Patients with severe COVID-19 develop lung failure and require oxygenation, which is often managed in Intensive Care Units. In addition, further complications include Acute Respiratory Distress Syndrome (ARDS), hemodynamic disbalance and shock. The subsequent multi organ dysfunction and failure is the main cause of death in coronavirus infections.
The multidisciplinary team around Prof. Dr. med. Wolfgang Huber report on their first case of severe COVID-19 that has been treated using the ADVOS (ADVanced Organ Support) therapy. In addition to applicable medical care the patient was treated with the ADVOS multi device – providing a multi organ support therapy based on blood purification for liver, lungs and kidneys and rapid correction of acid-base balance disorders, including CO2 removal.
During the continuous treatment using the ADVOS therapy the patient showed a noticeable improvement of the circulatory parameters, which led the team at the University Hospital rechts der Isar to conclude that less invasive approaches, like the ADVOS therapy, might be a viable treatment option for old-age-COVID-19 patients with multi organ failure.1
Assoc. Prof. Dr. med Bernhard Kreymann, founder and ADVITOS CEO, and his team are working closely with the hospitals using the ADVOS therapy. “By working together, we can ensure that the benefits of the ADVOS therapy are maximized when treating patients. We have recently improved the therapy to remove even more CO2 from the blood and therefore buy these patients more time to treat superinfections and the coronavirus itself.”
Similar results have been reported by Prof. Dr. med. Valentin Fuhrmann et. al. in their case series with 34 critically ill patients with multi organ failure.2 In these cases, the ADVOS multi device was able to correct acidosis (low blood pH), remove CO2 from the blood and eliminate water-soluble and protein-bound substances significantly. As a result, a lower mortality rate than expected could be observed in multi organ failure patients treated with the ADVOS multi.
The ADVOS therapy is designed to address the consequences of different failing organs at once by means of blood purification. As such it provides patient fluid management, renal replacement, liver and lung support in one set up. Especially the removal of CO2 from the patient’s blood and the direct blood pH correction are likely to be of benefit for patients with respiratory failure and acidosis.
Munich, 30th June 2020 – ADVITOS is one of 36 companies to receive funding from the European Innovation Council to fight the coronavirus pandemic.
In March 2020, the European Innovation Council (EIC) launched an urgent call for innovative companies to apply for EIC Accelerator funding as a response to the Corona outbreak. Almost 4,000 start-ups and small businesses applied – with over 1,400 focusing on testing, treating, and preventing the coronavirus. Following virtual interviews with the shortlisted companies, 36 projects were selected to receive funding to keep fighting the coronavirus. ADVITOS is one of only four selected companies from Germany.
Most people dying from the coronavirus suffer from a severe multiorgan dysfunction. That means that the main organs of the patients – the liver, lung, and kidneys – are not functioning correctly, adding a serious pathology to the lung failure caused by the viral infection. To positively influence the treatment of Covid-19 patients, it makes sense to involve a device capable of handling all these organs simultaneously for better results. The ADVOS therapy does exactly that. It supports the liver, lung, and kidneys as well as the direct pH correction of the blood in one single device and therefore has the potential to increase the chances of survival in severely ill Covid-19 patients.
Assoc. Prof. Dr. med. Bernhard Kreymann, inventor of the ADVOS therapy and CEO of ADVITOS, said: “We are honored and proud to receive the support of the European Innovation Council. This funding will further develop the ADVOS therapy and in this way facilitate the availability of this highly reliable treatment option for intensive care patients affected by Covid-19.”
Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The enormous talent and pioneering ideas of innovative European companies give us hope. By increasing our support for the European Innovation Council, we are unlocking their potential and can better tackle the corona virus and help build Europe. The EIC has responded quickly to the corona crisis and has demonstrated the flexibility and effectiveness of EU funding.”
The EIC is supported through the European Commission’s Horizon 2020 Framework Programme for Research and Innovation.
For more information about the EIC visit: https://ec.europa.eu/commission/presscorner/detail/en/ip_20_1007
We mourn for our long-time colleague and friend Prof. Dr. Wolfgang Huber.
Prof. Dr. Huber was an extraordinary personality and an outstanding doctor and researcher. During years of cooperation he was significantly involved in the development of the ADVOS therapy. Without him our therapy would not exist in this form today.
Assoc. Prof. Dr. med. Bernhard Kreymann, nephrologist and CEO of ADVITOS, says: “Throughout the past decades Prof. Dr. Huber was a reference in critical care medicine and clinical development. He was a true expert in extracorporeal organ support. During his career, he has followed innovation and excellence in the treatment of his patients and was a great teacher for his students, his staff and partners.
In fact, he was one of the pioneers in the clinical ADVOS therapy application. He contributed a lot in the development of the ADVOS therapy as a sound believer in its therapy concept and potential benefit for critically ill patients. The ADVITOS family loses a great partner, but above all, we lose a friend. Thank you, Wolfgang! Rest in Peace.“
Our deepest sympathy goes out to his loved ones.
Munich, 24th April 2020 – ADVITOS, a Munich based company, is currently being used in Intensive Care Units next to ventilators to save lives of people suffering from Covid-19.
ADVITOS’s patented medical devices, unique in the world, can support simultaneously three organs, (i.e. liver, lung & kidneys) and at the same time, adjust for blood pH balance. The ADVOS multi devices are currently being used to support patients suffering from Covid-19 in the hospital rechts der Isar in Munich, Germany, and are so far showing good results.
Assoc. Prof. Dr. med. Bernhard Kreymann, nephrologist and inventor of this technology is telling us why: “As you know, most people dying from Covid-19 have a certain age, and actually do suffer from Multiple Organ Failure (MOF) eventually. In simple terms, the kidneys, the heart, the liver and the lung of these patients are not functioning correctly which adds a serious pathology to the lung failure caused by the coronavirus. To help these patients it makes sense to involve a device capable of handling all these organs simultaneously for better results”.
The so called ADVOS multi device is already being used in 20 hospitals in Germany over the last 2 years and has helped to save the lives of many patients. Generic studies (not involving Covid-19 patients) have demonstrated that this technology is drastically improving the survival rate of patients from a very low 10% for people severely sick, to up to 50%. The fact that the organs of the patients are treated through a single procedure have visible medical benefits and simplifies the tasks and complexity of the treatments for the physicians and nurses. Yet, in order to further facilitate the usage of this device, the company is currently adding the most advanced digital technologies, using artificial intelligence, into the control systems of the machine.
500,000 people are dying each year from MOF in Europe and North America. With the outbreak of the Covid-19, these statistics are likely to become even much worse. “Thousands of patients suffering from Covid-19 would need such a treatment with an ADVOS multi device, precisely because a liver failure on top of a lung dysfunction is directly related to the mortality rate, and this hold true for Covid-19.” adds Assoc. Prof. Dr. med. Kreymann.
The ADVOS therapy has been in the spotlight on television recently (SAT1.Bayern 11.04.2020 17:00) and the outcome of the current clinical studies involving patients with Covid-19 is promising, but this will still take a few weeks to get the final results. In addition, the publication of the results in medical journals will take longer. Nevertheless, the development of another innovative procedure is on its way, involving further digital technologies, to be ready on time for the future outbreaks of such bad viruses.
Munich, 30th March 2020 – ADVITOS paves the way to internationalization by recruiting Dr. Stephan Aldinger as the new Head of Sales & Marketing International.
Stephan started his professional career as the co-founder and Member of the Executive Board of TERAKLIN, a medical device business which focused on implementing a new liver support therapy (MARS). The company was later acquired by Gambro in 2004, where he took on the role of VP R&D Portfolio & Marketing for the Acute Therapies Business Unit.
In 2014, Stephan joined Baxter International Inc. as Director Therapy Marketing Acute Renal for the EMEA region and was responsible for the strategic marketing and new product launches.
Stephan, who has a PhD in Chemistry, is very excited to be part of the ADVITOS family. “I’m thrilled about the new options of the ADVOS therapy and this new approach which can significantly improve the therapy outcomes of critically ill patients. Now that ADVITOS has already achieved success on the German market, I am particularly looking forward to the extremely exciting challenge of establishing the therapy in other markets.”
When Stephan is not pursuing his passion to connect science and innovation with marketing and strategy, he is enjoying heavy metal concerts and doing some DIY work on his house extension.
Munich, 24th February 2020 – ADVITOS announces the appointment of Dr. Philipp Stolka as new Head of Research and Development with immediate effect.
Philipp joined the company in October 2019 as Deputy Head of Research and Development. Prior to this, Philipp was Chief Technology Officer and Chief Science Officer at Clear Guide Medical Inc., a medtech company in Baltimore, MD, USA that he co-founded in 2010 and where he developed image guidance systems for ultrasound-based interventions.
ADVITOS CEO and founder, Assoc. Prof. Dr. med. Bernhard Kreymann, said: “I’m delighted to welcome Philipp in our team. Philipp’s previous experiences will prove extremely valuable to us at ADVITOS as we continue our journey to grow even further and establish our innovative therapy in more markets.”
Philipp studied Computer Science at the Technical University of Kaiserslautern and received his doctorate at the University of Bayreuth. He then moved to Baltimore where he worked as a visiting and postdoctoral researcher at the Johns Hopkins University. In his 20 years of academic and professional career he specialized early on in the field of medical technology and registered more than ten international patents.
In addition to supervising various product developments and collaborating on numerous research projects, Philipp somehow also found the time to learn five additional languages and enjoy bicycle trips with his family.
Munich, 12th December 2019 – ADVITOS prevails against 5 competitors at the Nordic Financial Ecosystem Forum and wins Best Investor Pitch Award
The third Nordic Financial Ecosystem Forum in Brussels is co-hosted by Nasdaq, EQT and the Nordic Securities Association. During the event European policymakers, opinion leaders as well as representatives from the financial industry and media interact on best practices and improvements to support access to capital by companies in the Nordic and Baltic region and the EU at large.
New for this year was the introduction of the Best Investor Pitch Award. Nasdaq said via its Twitter account that it doesn’t matter if you are preparing for an IPO or looking to raise capital in the private market, you need to get investor attention. Therefore, six growth companies, selected together with the European Business Angel Network, competed for the best investor pitch– with ADVITOS being the winner.
“It is essential for young companies like ADVITOS to address potential investors and to interact with them. To be honored with the Best Investor Pitch Award is a great achievement for us and will provide us with visibility to new investors,” says Catherine Schreiber, Deputy Managing Director of ADVITOS. “The display on the Nasdaq tower in Times Square in New York is another added bonus.”
Munich, 02nd December 2019 – After a final pitch contest ADVITOS takes the third place among the MedTech companies.
21 finalists in the categories MedTech, BioTech and Digital Health had been training and competing since spring 2019 to reach the finals of the European Health Catapult (EHC). The biggest pitch contest organised by EIT Health, EHC is designed to identify and accelerate promising European start-ups in the categories of Biotech, Medtech and Digital Health. The winners were announced on the evening of the 2nd December 2019, during the first day of the EIT Health Summit.
“The EIT Health Catapult provides a high-profile audience for us and we are proud that we made it to the podium”, says Assoc. Prof. Dr. med. Bernhard Kreymann, founder and CEO of ADVITOS. “The team at ADVITOS put a lot of hard work into this competition and we are very happy with such a great result.“
To view the video that shows what ADVITOS is all about and which was shown during the final pitch visit: https://youtu.be/NFQY-J0rXMw
Munich, 11th November 2019 – With a growth rate of 680 percent, the Munich-based company ADVITOS manages to reach 27th place in the Deloitte Technology Fast 50 2019.
With the Technology Fast 50 Award Deloitte annually honors the fastest-growing technology companies in the sectors of Hardware, Software, Communications, Media & Entertainment, Healthcare & Life Sciences, Environmental Technology and FinTech.
ADVITOS is the only listed MedTech company of the Technology Fast 50 Award and achieves the 27th place.
The ranking is based on the growth in sales over the last four financial years (2015 – 2018). ADVITOS was able to record a growth of 680 percent in this period. That was achieved with the commercialization of the inhouse-developed, CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device.
“We are very excited to be listed in the prestigious Deloitte Technology Fast 50 2019.”, says Assoc. Prof. Dr. med. Bernhard Kreymann, inventor of the ADVOS procedure, founder and CEO of ADVITOS GmbH. “It is a great recognition for the entire team who has worked very hard to make this happen. Further, this will give us visibility to investors and new customers which in turn will help us with further growth and the establishment of our innovative therapy in other markets.”
About ADVITOS – ADVITOS developed the CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device. ADVOS improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, ADVOS enables treatment of acid-base disbalances through patient individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading hospitals throughout Germany and is on its way to penetrating the international market.